123 related articles for article (PubMed ID: 1828377)
21. In vitro activity of oxacillin, vancomycin and teicoplanin against staphylococci isolated from patients on surgical and coronary intensive care units.
Kucukates E; Nalan Karayel E; Gultekin N; Okuyan E; Kansiz E; Gurler N
Int J Antimicrob Agents; 2004 Aug; 24(2):193-4. PubMed ID: 15288323
[No Abstract] [Full Text] [Related]
22. Teicoplanin-resistant coagulase-negative staphylococcus.
Wilson AP; O'Hare MD; Felmingham D; Grüneberg RN
Lancet; 1986 Oct; 2(8513):973. PubMed ID: 2877149
[No Abstract] [Full Text] [Related]
23. The bactericidal activity of vancomycin and teicoplanin against methicillin-resistant strains of coagulase negative Staphylococcus spp.
O'Hare MD; Felmingham D; Grüneberg RN
J Antimicrob Chemother; 1989 May; 23(5):800-2. PubMed ID: 2527220
[No Abstract] [Full Text] [Related]
24. Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
Roussel-Delvallez M; Wallet F; Barbiery P; Courcol RJ
J Chemother; 1997 Feb; 9(1):5-8. PubMed ID: 9106011
[TBL] [Abstract][Full Text] [Related]
25. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
26. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital.
Sloos JH; van de Klundert JA; Dijkshoorn L; van Boven CP
J Antimicrob Chemother; 1998 Dec; 42(6):787-91. PubMed ID: 10052903
[TBL] [Abstract][Full Text] [Related]
27. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998.
Santos Sanches I; Mato R; de Lencastre H; Tomasz A;
Microb Drug Resist; 2000; 6(3):199-211. PubMed ID: 11144420
[TBL] [Abstract][Full Text] [Related]
28. Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci.
Domaracki BE; Evans A; Preston KE; Fraimow H; Venezia RA
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):143-50. PubMed ID: 9665294
[TBL] [Abstract][Full Text] [Related]
29. [Comparative study of the bactericidal activity of cefepime and cefpirome in association with glycopeptides against Staphylococci sensitive and resistant to methicillin].
Husson MO; Fruchart A; Izard D
Pathol Biol (Paris); 1998 Apr; 46(4):279-83. PubMed ID: 9769909
[TBL] [Abstract][Full Text] [Related]
30. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
32. Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative Staphylococci isolated from orthopedic-device-associated infections.
Cremniter J; Slassi A; Quincampoix JC; Sivadon-Tardy V; Bauer T; Porcher R; Lortat-Jacob A; Piriou P; Judet T; Herrmann JL; Gaillard JL; Rottman M
J Clin Microbiol; 2010 Apr; 48(4):1428-31. PubMed ID: 20164270
[TBL] [Abstract][Full Text] [Related]
33. Activity of LY146032 and vancomycin against coagulase-negative staphylococci.
Low DE; Poon R
Eur J Clin Microbiol; 1987 Apr; 6(2):190. PubMed ID: 3595581
[No Abstract] [Full Text] [Related]
34. Teicoplanin-resistant coagulase-negative staphylococci.
Brumeitt W; Hamilton-Miller JM; Neville LO
Lancet; 1987 Feb; 1(8528):328. PubMed ID: 2880140
[No Abstract] [Full Text] [Related]
35. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
Del' Alamo L; Cereda RF; Tosin I; Miranda EA; Sader HS
Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
[TBL] [Abstract][Full Text] [Related]
36. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R
J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064
[TBL] [Abstract][Full Text] [Related]
37. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin.
Cooper MA; Jin YF; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1990 Aug; 26(2):203-7. PubMed ID: 2145256
[TBL] [Abstract][Full Text] [Related]
38. The effect of anaerobiosis on antistaphylococcal antibiotics.
Tsukayama DT; Guay DR; Gustilo RB; Wicklund B; Gruninger R; Peterson PK
Orthopedics; 1988 Sep; 11(9):1285-9. PubMed ID: 2971930
[TBL] [Abstract][Full Text] [Related]
39. [Teicoplanin and vancomycin susceptibility in Staphylococcus aureus and coagulase-negative staphylococci].
Caiaffa Filho HH; Lima Mde P; Sinto SI; Andriolo A; Mendes CM
Rev Assoc Med Bras (1992); 1994; 40(2):77-80. PubMed ID: 7820154
[TBL] [Abstract][Full Text] [Related]
40. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
Betriu C; Redondo M; Boloix A; Gómez M; Culebras E; Picazo JJ
J Antimicrob Chemother; 2001 Dec; 48(6):911-3. PubMed ID: 11733478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
